MILAN (AIMnews.it) - Kolinpharma semiannual report approved. On June 30th, 2018 the value of production amounted to 4.1 million euros, it was 2.1 million in the first half of 2017. Revenues grew by 98% to 2.7 million euros. The number of medical prescriptions also increased (+ 49%). EBITDA amounted to 0.3 million euros, compared to 0.1 million on 30th June 2017, and benefited from the increase in revenues despite the sustained growth of the organisational structure. The scientific and medical experts of medicine are today at 65 (a year before they were 45). The EBITDA margin is 10% compared to 7.5% in the first half of 2017. EBIT is substantially breakeven (€ 0.089 million) and an improvement compared to 30th June 2017 (€ 0.1 million) after amortisation and depreciation, at € 0.4 million (€ 0.3 million on 30th June 2017). The Net Financial Position is € 0.7 million, compared to € 2.5 million on 31st December 2017. "Our group's growth continues, and is reflected in the positive economic and financial results achieved in the first six months of 2018 - says Emanuele Lusenti, co-founder and AD of KOLINPHARMA® -. The status of a listed company has helped us to improve relations with credit institutions and suppliers, allowing us also to consolidate our development path through the expansion of the network of scientific and medical experts, the certification of the quality of our products and collaboration with leading universities with the aim of encouraging ever-increasing research in the nutraceutical field, which has now become an integral part of our business model."